Lead Product(s) : Pemafibrate,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Partnership
Kowa and DKSH Debut Triglycerides Lowering Medicine, Parmodia®, in Malaysia
Details : DKSH will undertake the responsibility for providing comprehensive Market Expansion Services for triglycerides lowering drug, Parmodia (pemafibrate).
Product Name : Parmodia
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 24, 2025
Lead Product(s) : Pemafibrate,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Merck & Co
Deal Size : Undisclosed
Deal Type : Partnership
DKSH Supports MSD’s Expansion with New Partnership to Improve Vaccine Access in Thailand
Details : DKSH will support the commercialization of human papillomavirus (HPV) vaccines, including Gardasil, in Thailand.
Product Name : Gardasil
Product Type : Vaccine
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Merck & Co
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Burosumab,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Partnership
DKSH and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific
Details : The partnership covers a promotion and distribution agreement for commercial rights of Kyowa’s established medicines, including Crysvita (burosumab), indicated for X-linked hypophosphatemia.
Product Name : Crysvita
Product Type : Antibody
Upfront Cash : Undisclosed
August 02, 2024
Lead Product(s) : Burosumab,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Zoledronic Acid,Inapplicable
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : SciGen
Deal Size : Undisclosed
Deal Type : Partnership
DKSH Has Successfully Entered into a Strategic Partnership with SciGen in Vietnam
Details : DKSH has enetered a strategic partnership with SciGen to supply Zometa (zoledronic acid) to the Vietnamese market. it is indicated for the treatment of Advanced cancers.
Product Name : Zometa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 21, 2023
Lead Product(s) : Zoledronic Acid,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : SciGen
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Bentonite,Citric Acid,Propylene Glycol
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Nuance Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Nuance Pharma Announces Partnership With DKSH To Launch Bentrio™ Nasal Spray In Hong Kong And Macau
Details : Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing promotion, supply chain, and distribution for Bentrio (bentonite) Nasal Spray sales operation in Hong Kong and Macau.
Product Name : Bentrio
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 28, 2022
Lead Product(s) : Bentonite,Citric Acid,Propylene Glycol
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Nuance Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Delgocitinib,Inapplicable
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Leo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regiona...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 29, 2022
Lead Product(s) : Delgocitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Leo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Eperisone Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
Details : Myonal (eperisone hydrochloride) is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders.
Product Name : Myonal
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 11, 2022
Lead Product(s) : Eperisone Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Denosumab,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Recipient : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The biosimilars planned under this agreement include biosimilar of Prolia® (denosumab, AVT03), Xgeva® (denosumab), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
July 09, 2022
Lead Product(s) : Denosumab,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Recipient : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
Alvotech and DKSH partner to bring key biosimilar to Asia
Details : Under the partnership, Alvotech Hf will be responsible for the development and supply of AVT02, while DKSH will oversee its registration and commercialization.
Product Name : Simlandi
Product Type : Antibody
Upfront Cash : Undisclosed
March 24, 2020
Lead Product(s) : Adalimumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
KEY PRODUCTS
Reset All
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.
